Aptamer Group PLC Wastewater monitoring system installed in UK
28 March 2022 - 5:01PM
RNS Non-Regulatory
TIDMAPTA
Aptamer Group PLC
28 March 2022
28 March 2022
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Optimer(R) -enabled wastewater monitoring system installed in UK
networks
Aptamer Group plc (AIM: APTA), the developer of novel Optimer(R)
binders to enable innovation in the life sciences industry, notes
the announcement today by DeepVerge plc (AIM:DVRG) that
Optimer-enabled Microtox(R) PD systems for the detection of
pathogens in wastewater have been installed at six sites across the
UK as part of the Environmental Monitoring for Health Protection
(EMHP) programme, with further installations expected in the UK
over the next few months as part of the programme.
MicrotoxPD from DeepVerge offers real-time detection and
monitoring of pathogens in wastewater and drinking water. This
system relies on specific Optimer binders to pathogen targets of
interest, coated on sensing chips within the units, to detect and
monitor SARS-CoV-2 in wastewater. The SARS-CoV-2 Optimer binders
were developed using the Company's proprietary discovery and
development platform, with scalable manufacture to support the
increased demand for sensors as more MicrotoxPD systems are
deployed. Aptamer Group was selected as the preferred affinity
ligand supplier for MicrotoxPD following performance evaluation of
the SARS-CoV-2 Optimers in parallel with ligands from different
suppliers.
An agreed extension of this partnership will see further Optimer
binders developed for Influenza A, Influenza B, Polio and Pepper
Mild Mottle Virus in wastewater and E.coli in drinking water to
further expand the detection capabilities of the MicrotoxPD
system.
The EMHP programme for wastewater monitoring is led by the Joint
Biosecurity Centre (which forms part of NHS Test & Trace),
DEFRA, academics and water companies. Data received from the
MircotoxPD units under the programme will allow public health
bodies to offer targeted containment in response to developing
disease outbreaks, and identification of the SARS-CoV-2 variants of
concern, each of which Aptamer's SARS-CoV-2 binder is able to
detect.
Arron Tolley, Chief Executive Officer of Aptamer Group,
commented: "We are really pleased to see the deployment of multiple
Optimer-enabled MicrotoxPD units under the Environmental Monitoring
for Health Protection programme. This will allow remote, real-time
monitoring of water pathogens, particularly SARS-CoV-2, for the
country to prepare for the next winter period. This Optimer-based
detection offers increased national and international water safety
through routine installations and monitoring, and we look forward
to supporting our partners at DeepVerge through the supply of
highly specific Optimer binders that enable specific and sensitive
pathogen detection on their platform."
- ENDS -
For further information, please contact:
Aptamer Group plc
Dr Arron Tolley - CEO /
Eleanor Brown (formerly Courtman-Stock) - CFO +44 (0) 1904 56 7790
Consilium Strategic Communications
Matthew Neal / Sukaina Virji / Lucy Featherstone +44 (0) 20 3709 5700
aptamergroup@consilium-comms.com
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer(R) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global antibody market is
currently worth over $145bn. Optimer binders are engineered to
address many of the issues found with alternative affinity
molecules, such as antibodies, and offer new, innovative solutions
to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global
pharma companies, diagnostic development companies, and research
institutes covering a range of targets and applications with the
objective of establishing royalty-bearing licenses. Through the
unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions
that support discovery and development across the Life
Sciences.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUBOWRUKUOUAR
(END) Dow Jones Newswires
March 28, 2022 02:01 ET (06:01 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024